Suggestions
Trevor Clancy
Experienced Cancer & Immunology Bioinformatics Scientist | Founder
Trevor Clancy is a prominent figure in the field of bioinformatics and cancer immunotherapy, with a significant role at NEC OncoImmunity AS. Here's a comprehensive overview of his professional background:
Professional Experience
Trevor Clancy has held several key positions throughout his career:
NEC OncoImmunity AS:
Nagasaki University:
- Professor (2023 - present)3
Institute for Cancer Research:
- Scientist3
Education
Clancy has a strong academic background in bioinformatics and biochemistry:
- Doctor of Philosophy (Ph.D.) in Bioinformatics (2008 - 2011)3
- Master of Science (M.Sc.) in Bioinformatics (2002 - 2003)3
- Bachelor of Science (B.Sc.) in Biochemistry (1997 - 2001)3
Research and Expertise
Trevor Clancy is an accomplished researcher in the field of bioinformatics and cancer immunotherapy:
- His work focuses on neoantigen prediction for personalized cancer immunotherapy and infectious disease vaccines1
- He has a significant publication record, with over 1,400 citations and an h-index of 212
- Clancy's research involves the application of artificial intelligence and machine learning in biotech1
Recent Developments
- In December 2023, Clancy announced his departure from the CSO role at NEC OncoImmunity AS after a 10-year journey with the company4
- He continues to serve as an advisor to NEC OncoImmunity AS1
Trevor Clancy's LinkedIn username is indeed trevor-clancy-55a351, as mentioned in the query.5
Highlights
Today is my last day as the Chief Scientific Officer at NEC OncoImmunity AS (NOI) after deciding to leave this amazing 10 year journey. A little sad because I will miss working with the amazingly talented team that we built. A wonderful team that uses their highly sought after skills on the cutting edge of AI, bioinformatics, and medicine to help cure individual cancer patients using immunotherapy and using AI to design universal vaccines to combat life-threatening infectious disease. It is also a happy day, because now I look forward to the next exciting chapter and the new challenges and opportunities that lie ahead. I would like to thank everyone who has contributed towards NOI’s success over the years – our success would not have been possible without you. I would particularly like to thank Anders Tuv and Jonas Einarsson at RADFORSK Investeringsstiftelse and Eivind Hovig who first believed in our vision. I would also like to thank our initial board members Svenn Widerberg and Tom A. Thorsen who with our initial chairman, Anders Tuv, helped guide the company and shape its early progress that eventually led to our successful growth and acquisition in 2019. In addition, I would like to thank Kjetil Holmefjord at Startuplab and Øyvind Grotmol for their committed and hands-on approach as second-round investors. I am also eternally grateful to our many collaborators, in particular Ludvig A Munthe, Jon Amund Kyte at Oslo University Hospital and Ola Myklebost at the University of Bergen (UiB), and our friends and collaborators at Ultimovacs and Lytix Biopharma. Also, huge kudos to Ketil F. Widerberg and Jutta Heix and the rest of the team at the Oslo Cancer Cluster for their tireless support and championing the company over the years. And finally, I would like to say a huge thank you to all of the NOI employees, past and present, in particular our NEC colleagues Akira Kitamura and Naoko Yamagata, and my co-founder Richard Stratford who has worked tirelessly on the project. I now look forward to following and supporting the company’s progress from a distance, initially as an advisor (for the next 6 months), and then subsequently as a proud member of the NOI alumni. Best wishes to everyone involved in the journey. I hope you all have a merry Christmas and prosperous New Year.
NEC OncoImmunity AS is recruiting a Quality Assurance Manager - building quality AI software to combat cancer and infectious disease https://lnkd.in/eNEzbsu
